Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 11
Submit an article Journal homepage
754
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Effects of Polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on Plasma Concentrations of Rosuvastatin and Lipid Response in Chinese Patients

Hon-Kit Lee1 Department of Medicine & Therapeutics, The Chinese University of Kong Kong, Shatin, Hong Kong SAR, China;2 Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong SAR, ChinaView further author information
,
Miao Hu1 Department of Medicine & Therapeutics, The Chinese University of Kong Kong, Shatin, Hong Kong SAR, ChinaView further author information
,
Sandra SH Lui1 Department of Medicine & Therapeutics, The Chinese University of Kong Kong, Shatin, Hong Kong SAR, ChinaView further author information
,
Chung-Shun Ho2 Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong SAR, ChinaView further author information
,
Chun-Kwok Wong2 Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong SAR, ChinaView further author information
&
Brian Tomlinson1 Department of Medicine & Therapeutics, The Chinese University of Kong Kong, Shatin, Hong Kong SAR, ChinaCorrespondence[email protected]
View further author information
Pages 1283-1294 | Received 17 Jun 2013, Published online: 09 Aug 2013

References

  • Arai H , YamamotoA, MatsuzawaY et al. Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000. J. Atheroscler. Thromb. 12(5) , 240–250 (2005).
  • Lee E , RyanS, BirminghamB et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78(4) , 330–341 (2005).
  • Tzeng TB , SchneckDW, BirminghamBK et al. Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Curr. Med. Res. Opin. 24(9) , 2575–2585 (2008).
  • White CM . A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J. Clin. Pharmacol.42(9) , 963–970 (2002).
  • Hu M , ToKK, MakVW, TomlinsonB. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin. Drug Metab. Toxicol.7(1) , 49–62 (2011).
  • Romaine SP , BaileyKM, HallAS, BalmforthAJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J.10(1) , 1–11 (2009).
  • Ho RH , TironaRG, LeakeBF et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130(6) , 1793–1806 (2006).
  • Choi JH , LeeMG, ChoJY, LeeJE, KimKH, ParkK. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Ther.83(2) , 251–257 (2008).
  • Pasanen MK , FredriksonH, NeuvonenPJ, NiemiM. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther.82(6) , 726–733 (2007).
  • Zhang W , YuBN, HeYJ et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta 373(1–2) , 99–103 (2006).
  • Keskitalo JE , ZolkO, FrommMF, KurkinenKJ, NeuvonenPJ, NiemiM. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther.86(2) , 197–203 (2009).
  • Tomlinson B , HuM, LeeVW et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin. Pharmacol. Ther.87(5) , 558–562 (2010).
  • Hu M , LuiSS, MakVW et al. Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenet. Genomics 20(10) , 634–637 (2010).
  • Chasman DI , GiulianiniF, MacfadyenJ, BarrattBJ, NybergF, RidkerPM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ. Cardiovasc. Genet.5(2) , 257–264 (2012).
  • Telbisz A , MullerM, Ozvegy-LaczkaC et al. Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochim. Biophys. Acta 1768(11) , 2698–2713 (2007).
  • Rodrigues AC , HirataMH, HirataRD. Impact of cholesterol on ABC and SLC transporters expression and function and its role in disposition variability to lipid-lowering drugs. Pharmacogenomics10(6) , 1007–1016 (2009).
  • Lee HK , HoCS, HuM, TomlinsonB, WongCK. Development and validation of a sensitive method for simultaneous determination of rosuvastatin and N-desmethyl rosuvastatin in human plasma using liquid chromatography/negative electrospray ionization/tandem mass spectrometry. Biomed. Chromatogr. doi:10.1002/bmc.2944 (2013) (Epub ahead of print).
  • Hu M , MakVWL, ChuTTY, WayeMMY, TomlinsonB. Pharmacogenetics of HMG-CoA reductase inhibitors: optimizing the prevention of coronary heart disease. Curr. Pharmacogenomics Pers. Med.7(1) , 1–26 (2009).
  • Zamber CP , LambaJK, YasudaK et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13(1) , 19–28 (2003).
  • Morisaki K , RobeyRW, Ozvegy-LaczkaC et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother. Pharmacol. 56(2) , 161–172 (2005).
  • Telbisz A , Ozvegy-LaczkaC, HegedusT, VaradiA, SarkadiB. Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein. Biochem. J.450(2) , 387–395 (2013).
  • Merino G , van Herwaarden AE, Wagenaar E, Jonker JW, Schinkel AH. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol. Pharmacol.67(5) , 1765–1771 (2005).
  • Martin PD , DaneAL, NwoseOM, SchneckDW, WarwickMJ. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J. Clin. Pharmacol.42(10) , 1116–1121 (2002).
  • Konig J , CuiY, NiesAT, KepplerD. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol.278(1) , G156–G164 (2000).
  • Iusuf D , van Esch A, Hobbs M et al. Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure. Mol. Pharmacol.83(5) , 919–929 (2013).
  • Watanabe T , KusuharaH, MaedaK, ShitaraY, SugiyamaY. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther.328(2) , 652–662 (2009).
  • Choi MK , ShinHJ, ChoiYL, DengJW, ShinJG, SongIS. Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica41(1) , 24–34 (2011).
  • Niemi M , PasanenMK, NeuvonenPJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther.80(4) , 356–366 (2006).
  • Kalliokoski A , NiemiM. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol.158(3) , 693–705 (2009).
  • Weiss J , SauerA, DivacN et al. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm. Drug Dispos. 31(2–3) , 150–161 (2010).
  • Sakaeda T , FujinoH, KomotoC et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm. Res. 23(3) , 506–512 (2006).
  • Macwan JS , IonitaIA, AkhlaghiF. A simple assay for the simultaneous determination of rosuvastatin acid, rosuvastatin-5S-lactone, and N-desmethyl rosuvastatin in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Anal. Bioanal. Chem.402(3) , 1217–1227 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.